Schering-Plough buys Millennium's stake in heart drug

Schering-Plough is buying out Millennium Pharmaceuticals' share of the heart drug Integrilin for a minimum of $250.5 million. Of that, $35.5 million will come as an upfront payment with a minimum of $85 million per year for the next two years in royalty payments. Millennium will also pocket $45 million to $50 million for stockpiles of the pharmaceutical.

"Acquiring the balance of US rights to Integrilin will give us direct control of this important therapy in its largest market. This is yet another long-term action we are taking to increase our importance to health providers and patients and to become a global leader in the very important area of cardiac care," said Fred Hassan, Schering-Plough chairman and CEO.

- read this story from for more

PLUS: Cambridge, Massachusetts-based Millennium swiftly announced that the revised deal with Schering-Plough would lead to the elimination of some 200 jobs. Story

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.